TL;DR
Niacinamide entered medicine in the 1930s as a cure for pellagra, a nutritional deficiency disease that was killing thousands of Americans every year. Its journey into skincare took six more decades. Procter and Gamble’s Olay research group, working on aging skin in the late 1990s, published the studies that built the modern niacinamide category. The 2002 Hakozaki paper on pigmentation and the 2005 Bissett paper on facial aging are the references that made the ingredient a serum staple.
Niacinamide is one of those ingredients with an almost embarrassingly thorough evidence base, which makes its slow path into mainstream skincare more puzzling. The molecule has been a well-characterized B vitamin since the 1930s. It has been a known nutritional therapy for nearly a century. It only became a skincare obsession in the last twenty years, mostly because of a sustained corporate research program at Procter and Gamble that almost nobody outside the industry knows about.
I find that part of the story interesting. The standard skincare narrative wants ingredients to come from independent dermatology labs and academic publications. Niacinamide came from a consumer-products company that ran better controlled trials on its anti-aging line than most academic groups managed on the same questions.
The pellagra era
Pellagra was a major public health crisis in the American South through the 1910s and 1920s, with mortality estimates ranging from several thousand to over ten thousand deaths per year at the peak. The disease produced the classic four Ds (dermatitis, diarrhea, dementia, death) and was endemic in populations dependent on corn-based diets without supplementary protein sources.
Joseph Goldberger, working for the US Public Health Service, demonstrated through a series of dietary experiments in the 1910s and 1920s that pellagra was a nutritional deficiency rather than an infection. The specific deficient factor was identified as nicotinic acid (niacin) by Conrad Elvehjem and colleagues at Wisconsin in 1937. Niacinamide, the amide form, was characterized shortly after and proved equally effective therapeutically with a better tolerability profile (no flushing reaction).
By the late 1940s, nicotinic acid and niacinamide were standard nutritional fortifications added to bread flour in the United States, which effectively eliminated pellagra as a clinical problem. The molecule sat in nutritional pharmacology for the next fifty years without anyone seriously pursuing its topical applications.
The Olay research program
The modern niacinamide story begins inside Procter and Gamble’s Olay R&D group in the 1990s. P&G had acquired the Olay brand in 1985 and was investing heavily in clinical research to support its anti-aging claims. The team, led at various points by Donald Bissett, Tomohiro Hakozaki, John Oblong, and others, ran a sustained program looking at B-vitamin derivatives and their effects on the skin.
The reasoning was biochemical. Niacinamide is the precursor to two key cellular cofactors, NAD+ and NADP+, which are involved in hundreds of enzymatic processes. The team hypothesized that delivering niacinamide topically might support a broad range of cellular functions in aging skin. The hypothesis turned out to be unusually correct.
The early publications came in the early 2000s. The 2002 Hakozaki paper in the British Journal of Dermatology showed that 5 percent topical niacinamide reduced melanosome transfer from melanocytes to keratinocytes, with measurable improvement in hyperpigmentation over weeks of use. The 2005 Bissett paper in Dermatologic Surgery extended the work to facial aging, showing improvement in fine lines, hyperpigmentation, redness, sallowness, and elasticity at the same concentration over 12 weeks. The team also published on barrier function, sebum regulation, and the molecular mechanism, building one of the most thorough single-ingredient evidence bases in cosmetic dermatology.
The Ordinary effect
Niacinamide entered mainstream awareness at a different pace from its scientific establishment. Through the 2000s and early 2010s it was present in many Olay and other mass-market products but rarely the headline ingredient. The shift came around 2016 with the launch of The Ordinary’s 10 percent niacinamide plus 1 percent zinc serum, which sold in volumes that surprised even Deciem.
The Ordinary’s pricing model (the niacinamide product retailed for under ten dollars) made the ingredient accessible at a scale that the premium category never matched. The internet skincare community, particularly the SkincareAddiction subreddit, adopted the product as a near-universal recommendation. Within a few years, niacinamide had a kind of cult status that mismatched its evidence base in the opposite direction from before. The ingredient that had been undersold was suddenly being marketed for things it could not really do (visible pore shrinkage being the most prominent overclaim).
The contrarian H2: niacinamide is a supporting actor that got cast as the lead
The current niacinamide moment frames the ingredient as a primary active. The marketing copy treats it like a flagship intervention. The evidence does not quite support that framing.
Niacinamide is unusually broad in its effects (barrier, pigmentation, redness, sebum, mild anti-aging) and unusually well-tolerated. It is also modest in each individual category. It will not match retinoic acid for fine lines, vitamin C for photoprotection, or azelaic acid for inflammatory pigmentation. What it does is improve every one of those endpoints by a small to moderate amount, with very low risk of irritation and excellent compatibility with other actives.
The right framing is that niacinamide is the ingredient you build a routine around, not the one you lead with. It is the supporting layer that lifts the performance of the other actives in the stack. The pore-cult positioning sells it as a hero ingredient when the literature describes a quiet workhorse.
The real numbers
The 2002 Hakozaki paper in the British Journal of Dermatology was a vehicle-controlled split-face study in 18 Japanese women with hyperpigmentation. After 8 weeks, 5 percent niacinamide produced a 35 percent reduction in pigmentation area compared with vehicle. The 2005 Bissett paper in Dermatologic Surgery enrolled 50 women in a 12-week vehicle-controlled split-face trial and reported statistically significant improvements on five separate aging endpoints, with effect sizes in the 10 to 25 percent range across measures.
A 2021 review in the Journal of Cosmetic Dermatology by Boo synthesized the niacinamide evidence across over 70 published studies and put the consensus position cleanly: 4 to 5 percent is the well-studied workhorse concentration, 10 percent is reasonable with slightly diminishing returns, and concentrations above 10 percent have minimal additional evidence and higher rates of mild irritation. The ingredient’s place in dermatology is established. The marketing inflation is recent.
What this means for your routine
The history suggests a few practical anchors. Start with 5 percent. Move to 10 percent if 5 percent does not deliver. The 12 to 20 percent products on the shelf are marketing, not science. Daily use is fine. Twice daily is fine. Niacinamide pairs with everything in a normal routine, including vitamin C, retinoids, acids, and SPF.
The ingredient is also a sensible base layer in a microbiome-supportive routine, because it improves barrier function without antimicrobial pressure. Our Microbiome Glow Serum sits in that tradition. For the broader thinking, see the niacinamide deep explainer, the 5 versus 10 percent comparison, and the barrier repair routine guide.
FAQ
Did Procter and Gamble really do most of the niacinamide research? A surprising amount of it, yes. The Olay research group’s publications through the 2000s and 2010s built the modern evidence base, and many of the references most often cited in skincare content originated there.
Is niacinamide the same as nicotinic acid? They are both vitamin B3 forms, but they behave differently. Niacinamide is the amide form, well-tolerated topically. Nicotinic acid (niacin) causes flushing and is generally used nutritionally, not in skincare.
Why does The Ordinary’s niacinamide product matter for the history? It made the ingredient accessible at a price that drove mass adoption. The science was already settled; The Ordinary’s launch built the consumer category.
Does niacinamide really shrink pores? Not physically. Pores look smaller after weeks of use because surrounding skin is firmer and sebum is cleaner. The visible effect is real; the mechanism is not pore shrinkage.
How long has niacinamide been used internally? Since the late 1930s, when pellagra fortification of flour began in the United States. It has one of the longest unbroken safety records in nutritional pharmacology.
Tag hub: More on niacinamide and how to use it
Sources
Hakozaki T et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology 2002. Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves aging facial skin appearance. Dermatologic Surgery 2005. Boo YC. Mechanistic basis and clinical evidence for the applications of nicotinamide in cosmetics. Journal of Cosmetic Dermatology 2021.